Lam Research reported Q4 2026 results on July 29 and the stock's post-earnings reaction has extended the damage from a bruising month, with the defining tension unchanged: the analyst community remains firmly bullish while the market keeps voting the other way.
The price move tells a stark story. LRCX closed Tuesday at $269.61, down 7.5% on the day and 16.3% on the week — taking the decline from the late-June peak near $433 to roughly 38%. The selloff remains a group event rather than a company-specific verdict. AMAT fell 7.8% on the day, MKSI dropped 9.6%, UCTT shed 10.9%, and ICHR lost 13%. KLAC and each fell roughly 6-7%. The semiconductor equipment complex is repricing as a unit, and LRCX is moving with the group.
The positioning picture remains remarkably calm given the price destruction. Short interest has ticked higher this week — up roughly 8.7% over seven sessions to 2.3% of the free float — but that reading is still low in absolute terms, and the borrow market underscores the absence of real short-side conviction. Cost to borrow has fallen nearly 43% over the past week to just 0.28%, and availability is essentially unlimited, with over a billion shares available to lend. These are not the conditions of a stock under siege from short sellers. The selling pressure continues to come from long holders exiting, not from bears building positions. Options positioning has drifted modestly more defensive, with the put/call ratio at 1.21 — above its 20-day average of 1.15 and running near the higher end of its recent range, though still well short of the 52-week defensive extreme of 1.37.
The Street has not moved. Every analyst action in recent weeks has been an upward target revision, with the mean consensus target sitting at $372 — now 38% above where the stock actually trades. Morgan Stanley raised its target to $404 on July 6. Evercore ISI lifted to $355 on July 20. Stifel moved to $425 and TD Cowen to $400 earlier in the month. The bull case rests on Lam's dominant etch market share, a projected WFE growth rate above 30% in 2027 as cleanroom constraints ease, and a customer roster anchored by TSMC, Samsung, and Micron. The bear case focuses on memory chipmaker concentration risk, increasing competitive pressure in etch and deposition, and the possibility that the broader WFE spending cycle slows before that 2027 acceleration materialises. The EV/EBITDA multiple has compressed sharply — down roughly 9.6x over the past 30 days — and the P/E has fallen more than 31 points over the same period, reflecting how aggressively the market has de-rated the stock even as earnings estimates have held. The EPS momentum factor ranks in the 96th percentile on a 30-day basis, meaning estimate revisions are still moving the right direction — the valuation collapse is a multiple story, not an earnings story.
Institutional ownership gives no obvious signal of capitulation at the top. BlackRock holds 10.6% of shares and added modestly in Q2. JP Morgan Asset Management added over 8 million shares in the same period. FMR added nearly 5.8 million. These are passive and semi-passive flows, not tactical conviction, but they suggest no large active managers have formally broken ranks. On the insider side, CEO Timothy Archer sold $11.7 million worth of shares on July 2 at $390 — prices now well above the market — while Chairman Talwalkar sold $6.1 million on July 13 at $335. Neither trade carries outsized significance on its own, and both were executed well above current levels, but the absence of any insider buying into the selloff is worth noting.
The ORTEX short score holds at 32.2, a low reading that has barely moved all month — consistent with the view that this decline is not being driven by short-side positioning. What to watch now is whether the Q4 results themselves shift the analyst consensus or prompt the first target cuts from firms that have spent the past month raising numbers into a falling stock.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
